Before the advent of HER2-targeted therapies, the 20–25% of patients with breast tumors that overexpressed HER2 had a poor prognosis. The approval and use of the HER2-targeted monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback